1.25 / AMA PRA Category 1 CreditsTM 1.25 / ANCC Contact Hours
Jointly provided by Amedco and MedNet, LLC.
Supported by: Amgen, Inc.
This webcast is intended to improve care of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This webcast is designed to meet the educational needs of primary care physicians, internal medicine, family medicine physicians, endocrinologists, cardiologists, lipidologists, diabetologists, registered nurses, pharmacists and allied healthcare professionals involved in the diagnosis and treatment of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia.
As a result of participating in the activity, learners should be better able to:
Outline risk assessment tools to identify individuals with residual atherosclerotic cardiovascular disease (ASCVD) risk such as familial hypercholesterolemia and/or statin intolerance who would benefit for PCSK9 therapy
Assess the latest clinical evidence on the impact of PCSK9 inhibitors evolocumab and alirocumab on LDL-C and cardiovascular risk in patients with ASCVD, familial hypercholesterolemia
Conflict Of Interest Disclosure Policy
It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.
James A. Underberg, MD, MS Lipidology & Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School & NYU Center for CV Prevention Director Bellevue Hospital Lipid Clinic New York, NY
Dr. Underberg discloses that he is a consultant: Amgen, Amarin; and was on speaker’s bureau of Amgen, Akcea, Regeneron, Sanofi, Amarin, Alexion; and on advisory board of Akcea, Amgen, Regeneron, Sanofi, Aegerion; and contracted research with Pfizer, Aegerion
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
James A. Underberg, MD, MS, listed his disclosures under the Faculty heading above.
Kamatham A. Naidu, PhD (MedNet, LLC), has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and MedNet, LLC. Amedco is accredited by the ACCME to provide continuing medical education for physicians.
Amedco designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and MedNet, LLC.
Maximum of 1.25 contact hours.
Disclosure of Unlabeled Use
It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
NON-ENDORSEMENT OF PRODUCTS Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
There are no fees for participating and receiving CME credit for this webcast. During the period May 11, 2018 through May 11, 2019, participants must read all the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
To obtain credit, a score of 80% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at 651-789-3730.
Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.